Autolus reiterates $120M-$135M 2026 AUCATZYL revenue guidance as it targets 65%-70% peak ALL gross margin
Source: SeekingAlpha
2026-05-14 20:11:34 ET
More on Autolus Therapeutics
- Autolus Therapeutics plc (AUTL) Q1 2026 Earnings Call Transcript
- Autolus Therapeutics plc 2026 Q1 - Results - Earnings Call Presentation
- Autolus Therapeutics plc (AUTL) Discusses Advances in B-cell Precursor Acute Lymphoblastic Leukemia Treatment and Clinical Trial Insights Transcript
- Autolus Therapeutics Q1 2026 Earnings Preview
- Autolus to cut about 13% of workforce in cost reduction initiative
Read the full article on Seeking Alpha
For further details see:
Autolus reiterates $120M-$135M 2026 AUCATZYL revenue guidance as it targets 65%-70% peak ALL gross margin
Autolus Therapeutics plc
NASDAQ: AUTL
AUTL Trading
15.56% G/L:
$1.82 Last:
873,346 Volume:
$1.62 Open:
AUTL Latest News
May 14, 2026 07:00:00 am
Autolus Therapeutics Reports First Quarter 2026 Financial Results and Business UpdatesMay 05, 2026 07:00:00 am
Autolus Therapeutics to Report First Quarter 2026 Financial Results and Host Conference Call on May 14, 2026April 29, 2026 04:05:00 pm
Autolus Therapeutics Announces Initiative to Support Operational Efficiency and Cost ReductionAUTL Stock Data
$387,238,481
109,839,996
N/A
49
N/A
Biotechnology & Life Sciences
Healthcare
GB
London
